SCHEMBL5145178

SCHEMBL5145178

O=C(O)c1ccc(-c2ccc(/C=C3\NC(=O)N(Cc4ccccc4F)C3=O)o2)cc1Cl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 13/20 0.75
TDP2 O95551 1/20 0.75
MAPT P10636 9/20 0.73
KDM4E B2RXH2 9/20 0.73
KMT2A Q03164 8/20 0.73
L3MBTL1 Q9Y468 8/20 0.73
POLB P06746 8/20 0.73
ALDH1A1 P00352 7/20 0.73
APEX1 P27695 7/20 0.73
MEN1 O00255 6/20 0.73
RECQL P46063 5/20 0.73
LMNA P02545 1/20 0.73
PLA2G1B P04054 1/20 0.73
DNMT1 P26358 1/20 0.73
ATG4B Q9Y4P1 1/20 0.73
PKM P14618 5/20 0.58
HTT P42858 1/20 0.58
CTDSP1 Q9GZU7 5/20 0.57
MAPK1 P28482 1/20 0.57
PTPN1 P18031 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145183 1.00 TDP1 (0.75) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL5145004 0.83 TDP1 (0.75) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL5145007 0.83 TDP1 (0.75) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL6393879 0.80 TDP1 (0.74) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL5146587 0.80 TDP1 (0.74) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL5147367 0.77 TDP1 (0.63) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL5147374 0.77 TDP1 (0.63) TDP1TDP2MAPTKDM4EKMT2A
SCHEMBL6395650 0.76 TDP1 (0.75) TDP1MAPTKDM4EKMT2AL3MBTL1
SCHEMBL6395653 0.76 TDP1 (0.75) TDP1MAPTKDM4EKMT2AL3MBTL1
SCHEMBL21852274 0.75 KDM4E (0.85) TDP1TDP2MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 TDP1 1996/4885TDP2 1526/4885MAPT 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.